一例口服胺碘酮致肺间质性病变的药学实践  

Pharmaceutical practice of a case of interstitial lung disease induced by oral amiodarone

作　　者：汪余嘉 陈家鑫 林敏华 WANG Yu-jia;CHEN Jia-xin;LIN Min-hua(Department of Clinical Pharmacy,Ningde Municipal Hospital Affiliated to Ningde Normal University,Ningde 352100,China;Collaborative Innovation Center of Active Ingredient research of She Medicine(2020Z03),Ningde Normal University,Ningde 352100,China)

机构地区：[1]宁德师范学院附属宁德市医院临床药学室,福建宁德352100 [2]宁德师范学院闽东畲药有效成分研究协同创新中心,福建宁德352100

出　　处：《中国处方药》2023年第12期102-106,共5页Journal of China Prescription Drug

基　　金：福建医科大学启航基金一般项目(2020QH1335)。

摘　　要：目的以1例口服胺碘酮致肺间质性病变的患者为例,探讨临床药师识别药物不良反应的策略。方法结合胺碘酮致肺间质性病变的特点、危险因素及可能机制,对胺碘酮与肺间质性病变的关联性进行评价,并开展药学监护与用药教育。结果该患者肺间质性病变与胺碘酮的因果关系评定等级为可能有关;患者对药物的不良反应认识及自我监护意识提高。结论临床药师通过整理分析患者病史及用药史,利用循证药学方法,可协助临床及早识别高危患者与药品不良反应,最大程度避免药源性损害。Objective To investigate the strategy of clinical pharmacists in identifying adverse drug reactions,using a case of interstitial lung disease caused by oral amiodarone as an illustrative example.Methods According to the characteristics,risk factors and possible mechanism of amiodaroneinduced interstitial lung disease,the correlation between amiodarone and interstitial lung disease was evaluated.Additionally,pharmaceutical care and medication education were implemented.Results The causal relationship between the interstitial lung disease and amiodarone was rated as probably related.The patient’s knowledge regarding adverse drug reactions and their self-monitoring awareness were enhanced.Conclusion Clinical pharmacists can use evidence-based pharmacy to assist clinical early identification of high-risk patients and adverse drug reactions,and avoid drug-induced damage to the greatest extent.This is achieved by collating and analyzing the patient's medical history and medication history.

关 键 词：胺碘酮 肺间质性病变 不良反应 临床药师 

分 类 号：R969[医药卫生—药理学]